395 related articles for article (PubMed ID: 29243123)
1. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
[TBL] [Abstract][Full Text] [Related]
2. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update on imaging techniques and screening of pancreatic cancer in high-risk individuals.
Kulkarni NM; Mannelli L; Zins M; Bhosale PR; Arif-Tiwari H; Brook OR; Hecht EM; Kastrinos F; Wang ZJ; Soloff EV; Tolat PP; Sangster G; Fleming J; Tamm EP; Kambadakone AR
Abdom Radiol (NY); 2020 Mar; 45(3):729-742. PubMed ID: 31768594
[TBL] [Abstract][Full Text] [Related]
3. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
4. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience.
Hamdy A; Ichikawa Y; Toyomasu Y; Nagata M; Nagasawa N; Nomoto Y; Sami H; Sakuma H
Radiology; 2019 Sep; 292(3):628-635. PubMed ID: 31287389
[TBL] [Abstract][Full Text] [Related]
5. What Can We Learn About Pancreatic Adenocarcinoma from Imaging?
Rosenthal M; Schawkat K; Muftah M; Jajoo K
Hematol Oncol Clin North Am; 2022 Oct; 36(5):911-928. PubMed ID: 36265990
[TBL] [Abstract][Full Text] [Related]
6. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.
Zhang Y; Huang ZX; Song B
World J Gastroenterol; 2021 Jun; 27(22):3037-3049. PubMed ID: 34168406
[TBL] [Abstract][Full Text] [Related]
7. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
[TBL] [Abstract][Full Text] [Related]
8. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
[No Abstract] [Full Text] [Related]
10. Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques.
Wang ZJ; Arif-Tiwari H; Zaheer A; Ameli S; Bhosale PR; Do RK; Goenka AH; Guimares AR; Sangster GP; Soloff EV; Tamm EP; Zins M; Kambadakone AR
Abdom Radiol (NY); 2020 Dec; 45(12):4273-4289. PubMed ID: 32936417
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Montemagno C; Cassim S; De Leiris N; Durivault J; Faraggi M; Pagès G
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203923
[TBL] [Abstract][Full Text] [Related]
13. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy.
Ciaravino V; Cardobi N; DE Robertis R; Capelli P; Melisi D; Simionato F; Marchegiani G; Salvia R; D'Onofrio M
Anticancer Res; 2018 Aug; 38(8):4889-4895. PubMed ID: 30061265
[TBL] [Abstract][Full Text] [Related]
14. Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma.
Qu C; Zeng PE; Wang HY; Yuan CH; Yuan HS; Xiu DR
J Magn Reson Imaging; 2022 Jun; 55(6):1625-1632. PubMed ID: 35132729
[TBL] [Abstract][Full Text] [Related]
15. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
16. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
[TBL] [Abstract][Full Text] [Related]
17. Multi-institutional survey on imaging practice patterns in pancreatic ductal adenocarcinoma.
Kambadakone AR; Zaheer A; Le O; Bhosale P; Meier J; Guimaraes AR; Shah Z; Hough DM; Mannelli L; Soloff E; Friedman A; Tamm E
Abdom Radiol (NY); 2018 Feb; 43(2):245-252. PubMed ID: 29277858
[TBL] [Abstract][Full Text] [Related]
18. Multimodal treatment of resectable pancreatic ductal adenocarcinoma.
Silvestris N; Brunetti O; Vasile E; Cellini F; Cataldo I; Pusceddu V; Cattaneo M; Partelli S; Scartozzi M; Aprile G; Casadei Gardini A; Morganti AG; Valentini V; Scarpa A; Falconi M; Calabrese A; Lorusso V; Reni M; Cascinu S
Crit Rev Oncol Hematol; 2017 Mar; 111():152-165. PubMed ID: 28259290
[TBL] [Abstract][Full Text] [Related]
19. ACR Appropriateness Criteria
; Qayyum A; Tamm EP; Kamel IR; Allen PJ; Arif-Tiwari H; Chernyak V; Gonda TA; Grajo JR; Hindman NM; Horowitz JM; Kaur H; McNamara MM; Noto RB; Srivastava PK; Lalani T
J Am Coll Radiol; 2017 Nov; 14(11S):S560-S569. PubMed ID: 29101993
[TBL] [Abstract][Full Text] [Related]
20. CT perfusion as a potential biomarker for pancreatic ductal adenocarcinoma during routine staging and restaging.
O'Malley RB; Cox D; Soloff EV; Zečević M; Green S; Coveler A; Busey JM; Wang CL
Abdom Radiol (NY); 2022 Nov; 47(11):3770-3781. PubMed ID: 35972550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]